Genfit S.A. (EPA:GNFT)

Market Cap	180.16M
Revenue (ttm)	45.13M
Net Income (ttm)	-38.76M
Shares Out	49.80M
EPS (ttm)	-0.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	136,938
Average Volume	183,968
Open	3.600
Previous Close	3.618
Day's Range	3.540 - 3.624
52-Week Range	2.620 - 5.630
Beta	1.33
RSI	49.52
Earnings Date	Dec 23, 2025

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 180
• Stock Exchange: Euronext Paris
• Ticker Symbol: GNFT